J. Crowley

J. Crowley, Kenji Suzuki, R. Rami-Porta, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, A. Nicholson, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours

J. Crowley, V. Rusch, L. Sobin, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

J. Crowley, G. Mulligan, D. Esseltine, 2016, Cancer cell.

Cure Models as a Useful Statistical Tool for Analyzing Survival

Bart Barlogie, Megan Othus, M. LeBlanc, 2012, Clinical Cancer Research.

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer

Hisao Asamura, Kari Chansky, J. Crowley, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Comparative Study on the SWOG Two-Stage Design Extension to Stop Early for Efficacy in Single Arm Phase II Trials

J. Crowley, A. Hoering, Monica Chaudhari, 2020 .

Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.

R J Carroll, R. Carroll, J. Crowley, 2000, Controlled clinical trials.

Randomized Phase IIDesigns

M. LeBlanc, J. Crowley, D. Sargent, 2009 .

A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a southwest oncology group study

J. Crowley, R. Livingston, C. Higano, 2004, Investigational New Drugs.

E- 19. Lung Cancer Clinical Trials: Principles and Pitfalls

J. Crowley, 2003 .

Testing Against Ordered Alternatives for Censored Survival Data

Stephanie Green, J. Crowley, S. Green, 1993 .

A general class of nonparametric tests for survival analysis.

J. Crowley, M. P. Jones, J Crowley, 1989, Biometrics.

Tests for differences in tumor incidence based on animal carcinogenesis experiments

Barbara McKnight, J. Crowley, B. McKnight, 1984 .

A k-Sample Median Test for Censored Data

Ron Brookmeyer, J. Crowley, R. Brookmeyer, 1982 .

Step‐function covariate effects in the proportional‐hazards model

Michael LeBlanc, M. LeBlanc, J. Crowley, 1995 .

Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial ( SELECT )

J. Crowley, J. Chin, I. Thompson, 2011 .

The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer

Kari Chansky, J. Crowley, P. Postmus, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Partitioning and peeling for constructing prognostic groups

Michael LeBlanc, Joth Jacobson, M. LeBlanc, 2002, Statistical methods in medical research.

Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer.

J. Crowley, R. Livingston, D. Gandara, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

Ian M Thompson, J. Crowley, I. Thompson, 2005, JAMA.

Challenges in clinical studies with multiple imaging probes.

F. O’Sullivan, J. Crowley, D. Mankoff, 2007, Nuclear medicine and biology.

Phase II Trials Using Time-to-Event Endpoints

J. Crowley, C. Tangen, 2005 .

Mutant DNA in Plasma of Lung Cancer Patients: Potential for Monitoring Response to Therapy

J. Crowley, J. Doroshow, D. Gandara, 2004, Annals of the New York Academy of Sciences.

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study

J. Crowley, T. Grogan, G. Weiss, 1995, Cancer.

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

J. Crowley, B. Barlogie, E. Tian, 2016, Blood Cancer Journal.

The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer

J. Crowley, A. Nicholson, V. Rusch, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ACUTE RENAL TOXICITY WITH COMBINED USE OF AMPHOTERICIN B AND CYCLOSPORINE AFTER MARROW TRANSPLANTATION

J. Crowley, H. Deeg, J. J. Crowley, 1983, Transplantation.

CORRELATION OF SERUM CYCLOSPORINE CONCENTRATION WITH RENAL DYSFUNCTION IN MARROW TRANSPLANT RECIPIENTS

J. Crowley, G. Yee, H. Deeg, 1985, Transplantation.

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer

J. Crowley, V. Rusch, M. Tsuboi, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Staging Manuals: the new era of data-driven revisions.

J. Crowley, V. Rusch, R. Rami-Porta, 2010, The Journal of thoracic and cardiovascular surgery.

Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007

J. Crowley, A. Nicholson, V. Rusch, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: A Renewed Call to Participation.

J. Crowley, V. Rusch, R. Rami-Porta, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia.

J. Crowley, B. Barlogie, S. Usmani, 2011, Clinical lymphoma, myeloma & leukemia.

Reply to J.C. Regelink et al

J. Crowley, B. Barlogie, P. Moreau, 2010 .

A graphical approach to the analysis of censored data

R. Gentleman, J. Crowley, 2005, Breast Cancer Research and Treatment.

Solitary Brain Metastasis: Results of an RTOG/SWOG Protocol Evaluation Surgery + RT versus RT Alone

J. Crowley, W. Sause, M. Rotman, 1990, American journal of clinical oncology.

DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies

G. Colditz, J. Crowley, 2011, Clinical Cancer Research.

Estimated impact of the Prostate Cancer Prevention Trial on population mortality

J. Crowley, M. Leblanc, I. Thompson, 2005, Cancer.

Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.

Dawn L Hershman, J. Crowley, C. Coltman, 2009, Journal of the National Cancer Institute.

The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification

Fergus Gleeson, Heber MacMahon, Jin Mo Goo, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Moving a randomized clinical trial into an observational cohort

J. Crowley, P. Goodman, C. Tangen, 2013, Clinical trials.

Remarks on the conservatism of sigma(0 -- E)2/E in survival data.

N. Breslow, J. Crowley, 1975, Biometrics.

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer

J. Crowley, P. Goldstraw, 2006 .

Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327)

J. Crowley, D. Gandara, W. Franklin, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer

J. Crowley, P. Postmus, F. Shepherd, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC/ITMIG Thymic Malignancies Staging Project: Development of a Stage Classification for Thymic Malignancies

J. Crowley, G. Giaccone, A. Nicholson, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: Data Elements for the Prospective Project

J. Crowley, V. Rusch, L. Sobin, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

We probably have the answer: now what is the question?

J. Crowley, R. Rami-Porta, P. Goldstraw, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study.

J. Crowley, R. Livingston, D. Gandara, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of etoposide and cisplatin with bis‐chloro‐ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study

J. Crowley, C. Coltman, R. Pazdur, 1990, Cancer.

E05-02: IASLC Staging Project: T-desriptors

J. Crowley, R. Rami-Porta, M. Tsuboi, 2007 .

The Impact of Additional Prognostic Factors on Survival and their Relationship with the Anatomical Extent of Disease Expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the Proposals for the 7th Edition

J. Crowley, J. V. van Meerbeeck, K. Chansky, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study.

J. Crowley, C. Coltman, R. Livingston, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of Tirapazamine Plus Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer (S0004)

J. Crowley, D. Gandara, L. Gaspar, 2004, Clinical Cancer Research.

Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study.

J. Crowley, L. Baker, L. Janaki, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma

J. Crowley, Hongwei Wang, B. Durie, 2017, Future oncology.

Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).

J. Crowley, K. Stelzer, R. Livingston, 1998, International journal of radiation oncology, biology, physics.

Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial.

J. Crowley, V. Rusch, R. Livingston, 1993, The Journal of thoracic and cardiovascular surgery.

Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials

J. Crowley, N. Saijo, Y. Nishiwaki, 2004 .

S9900: Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial

J. Crowley, R. Ginsberg, P. Bunn, 2007 .

S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC)

J. Crowley, J. Jett, H. Lenz, 2008 .

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

Robert J. Mayer, Walter J. Curran, J. Crowley, 2001, Journal of the National Cancer Institute.

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer

Elisabeth Brambilla, Edward F. Patz, Kari Chansky, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126.

J. Crowley, D. Gandara, W. Franklin, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

J. Crowley, D. Gandara, W. Franklin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126).

J. Crowley, F. Hirsch, D. Gandara, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

国际肺癌研究会分期项目——采用外科治疗的非小细胞肺癌的预后因素和病理TNM分期

John J. Crowley, Kari Chansky, J. Crowley, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials.

J. Crowley, C. Coltman, S. Martino, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials.

J. Crowley, I. Thompson, P. Goodman, 2004, The Journal of urology.

Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Michael M Lieber, J Michael Gaziano, Ian M Thompson, 2005, Journal of the National Cancer Institute.

J. Crowley, R. Glynn, I. Thompson, 2015, JAMA ophthalmology.

Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

J. Crowley, M. Spitz, J. Stanford, 2004, Cancer Causes & Control.

19 Utility of the enrollment period in the Prostate Cancer Prevention Trial (PCPT)

J. Crowley, I. Thompson, P. Goodman, 1997 .

The influence of finasteride on the development of prostate cancer.

Michael M Lieber, Ian M Thompson, Scott M Lippman, 2003, The New England journal of medicine.

The prostate cancer prevention trial: design, biases and interpretation of study results.

J. Crowley, I. Thompson, P. Goodman, 2006, The Journal of urology.

Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru

J. Crowley, K. Boehnke, L. Baker, 2017, Infection and drug resistance.

Quality of life in advanced non-small-cell lung cancer: Results of a Southwest Oncology Group randomized trial

J. Crowley, K. Kelly, P. Grevstad, 2002, Quality of Life Research.

Predictors of survival following relapse or progression of small cell lung cancer. Southwest oncology group study 8605 report and analysis of recurrent disease data base

J. Crowley, R. Livingston, D. Gandara, 1993, Cancer.

Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience.

J. Crowley, R. Livingston, J. Crowley, 1991, Chest.

Oncology clinical trials

P. Müller, T. Lai, G. Rosner, 2013 .

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

J. Crowley, B. Barlogie, E. Tian, 2016, Blood cancer journal.

Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma

J. Crowley, B. Barlogie, K. Stratton, 2014, Leukemia.

Data monitoring committees for Southwest Oncology Group clinical trials.

J. Crowley, S. Green, 1993, Statistics in medicine.

Data Monitoring Committees and early stopping guidelines: the Southwest Oncology Group experience.

J. Crowley, S. Green, P. Y. Liu, 1994, Statistics in medicine.

Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232.

J. Crowley, B. Barlogie, D. Moore, 2007 .

Implementation of the Prostate Cancer Prevention Trial (PCPT).

J. Crowley, I. Thompson, P. Goodman, 2004, Controlled clinical trials.

Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study

J. Crowley, R. Livingston, D. Gandara, 1997, Cancer Chemotherapy and Pharmacology.

A Large Sample Study of Generalized Maximum Likelihood Estimators from Incomplete Data Via Self-Consistency

J. Crowley, W. Tsai, 1985 .

A pilot study of mitomycin-C and tamoxifen (MT) versus dibromodulcitol, adriamycin, and tamoxifen (DAT).

J. Crowley, D. Tormey, G. Falkson, 1982, American journal of clinical oncology.

Effect Of Vitamin E And Selenium On Rate Of Decline In FEV1: The Respiratory Ancillary Study To The Selenium And Vitamin E Cancer Prevention Trial (SELECT)

J. Crowley, P. Goodman, C. Tangen, 2011, ATS 2011.

Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer.

Charles R. Thomas, J. Crowley, R. Livingston, 2001, Lung cancer.

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).

J. Crowley, B. Barlogie, D. Moore, 2010, Blood.

Teniposide (VM‐26) as a single drug treatment for patients with extensive small cell lung carcinoma

J. Crowley, G. Weiss, R. Livingston, 1997, Cancer.

Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma: A phase II study of the Southwest Oncology Group

J. Crowley, R. Figlin, R. Livingston, 1996, Cancer.

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study

J. Crowley, H. Eyre, K. Jaeckle, 2005, Journal of Neuro-Oncology.

Dibromodulcitol and adriamycin +/- tamoxifen in advanced breast cancer.

J. Crowley, D. Tormey, J. Voelkel, 1982, American journal of clinical oncology.

Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study

J. Crowley, R. Livingston, F. Muggia, 2004, Cancer Chemotherapy and Pharmacology.

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.

J. Crowley, K. Kelly, A. Wozniak, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).

J. Crowley, B. Barlogie, M. Dhodapkar, 2003, Seminars in oncology.

Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.

J. Crowley, A. Wozniak, G. Weiss, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2: A SWOG phase II trial (S0027)

J. Crowley, D. Gandara, K. Chansky, 2004 .

Prolonged, alternating chemotherapy for extensive small cell lung cancer. A southwest oncology group study

J. Crowley, R. Livingston, F. Meyers, 1993 .

Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group.

J. Crowley, R. Livingston, D. Gandara, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Total therapy (TT) for myeloma (MM)—10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2

J. Crowley, B. Barlogie, J. Shaughnessy, 2008 .

Investigational Drug Steering Committee Trial Design Task Force of the National Cancer Institute Therapeutics : Consensus Recommendations from the Clinical The Design of Phase II Clinical Trials Testing Cancer

D. Berry, J. Crowley, S. Groshen, 2010 .

Southwest Oncology Group: two decades of experience in non-small cell lung cancer.

J. Crowley, D. Gandara, L. Gaspar, 2005, Seminars in oncology.

Use of bortezomib (BOR) pharmacogenomics (PG) to identify mechanisms of drug resistance and predict survival in multiple myeloma (MM) treated with total therapy 3 (TT3).

J. Crowley, B. Barlogie, J. Shaughnessy, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II evaluation of bisantrene in refractory multiple myeloma

J. Crowley, B. Cheson, C. Coltman, 1991, Investigational New Drugs.

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

J Crowley, B E Storer, T A Gooley, 1999, Statistics in medicine.

Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.

J. Crowley, K. Kelly, P. Bunn, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

International prognostic scoring system for Waldenstrom macroglobulinemia.

J. Crowley, B. Barlogie, M. Dimopoulos, 2009, Blood.

Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.

J. Blasko, J. Crowley, R. Livingston, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342.

J. Crowley, R. Herbst, K. Kelly, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study.

J. Crowley, R. Livingston, K. Albain, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-89 S0003: Paclitaxel/carboplatin (PC) versus PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III southwest oncology group (SWOG) trial

J. Crowley, D. Gandara, P. Lara, 2003 .

Concurrent chemotherapy and radiotherapy for limited small-cell carcinoma of the lung: a Southwest Oncology Group Study.

J. Crowley, L. Janaki, R. Vance, 1986, Seminars in oncology.

Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial.

J. Crowley, H. Eyre, T. Pollock, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture.

J. Crowley, M. Leblanc, I. Thompson, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors

J. Crowley, H. Eyre, F. Vogel, 1991, Investigational new drugs.

macroglobulinemia International prognostic scoring system for Waldenstrom's

J. Crowley, M. Dimopoulos, M. Dhodapkar, 2009 .

Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience.

J. Crowley, J. Jacobson, R. Alexanian, 2001, Seminars in hematology.

The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer

Hisao Asamura, Kari Chansky, Ramón Rami-Porta, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Design of the Prostate Cancer Prevention Trial (PCPT).

J. Crowley, B. Kramer, I. Thompson, 1995, Controlled clinical trials.

Designs Using Time-to-Event Endpoints/Single-Arm versus Randomized Phase II Designs

J. Crowley, C. Tangen, 2012 .

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

J. Crowley, I. Thompson, P. Goodman, 2009, JAMA.

Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs. nalidixic acid.

J. Crowley, P. Wiernik, S. Schimpff, 1983, The Journal of infectious diseases.

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.

J. Crowley, B. Barlogie, G. Weiss, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.

J. Crowley, B. Barlogie, M. Dhodapkar, 2015, Blood.

Chemoprevention of prostate cancer: The prostate cancer prevention trial

J. Crowley, I. Thompson, C. Coltman, 1997, The Prostate.

Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.

J. Crowley, D. Gandara, W. Franklin, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical studies of a fast homoarginine-sensitive alkaline phosphatase in patients with cancer.

J. Crowley, T. E. Davis, L. Kahan, 1981, Cancer research.

Recurrent infection with herpes simplex virus after marrow transplantation: role of the specific immune response and acyclovir treatment.

J. Crowley, J. Meyers, J. Wade, 1984, The Journal of infectious diseases.

Whole brain irradiation and intrathecal Methotrexate in the treatment of solid tumor leptomeningeal metastases — A Southwest Oncology Group study

J. Crowley, W. Sause, H. Eyre, 1988, Journal of Neuro-Oncology.

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

J. Crowley, I. Wistuba, H. Tawbi, 2017, The Lancet. Oncology.

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

J. Crowley, J. Jett, D. Gandara, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy

J. Crowley, B. Barlogie, J. Shaughnessy, 2007, The Journal of experimental medicine.

Should the 7th Edition of the Lung Cancer Stage Classification System Change Treatment Algorithms in Non-small Cell Lung Cancer?

J. Crowley, R. Rami-Porta, L. Tanoue, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours

J. Crowley, L. Sobin, M. Krasnik, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors

J. Crowley, G. Giaccone, A. Nicholson, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors.

J. Crowley, G. Giaccone, A. Nicholson, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The revised TNM staging system for lung cancer.

J. Crowley, R. Rami-Porta, P. Goldstraw, 2009, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119

J. Crowley, D. Gandara, K. Chansky, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Handbook of Statistics in Clinical Oncology, Second Edition

John Crowley, Antje Hoering, J. Crowley, 2005 .

Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.

J. Crowley, R. Livingston, D. Gandara, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison.

J. Crowley, H. Deeg, F. Appelbaum, 1984, Annals of internal medicine.

The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer

J. Crowley, R. Rami-Porta, M. Krasnik, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

J. Crowley, R. Rami-Porta, A. Turrisi, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho-Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer

J. Crowley, V. Rusch, R. Rami-Porta, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer

J. Crowley, R. Rami-Porta, M. Tsuboi, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.

M Markman, W J Curran, T A Louis, 2001, Journal of the National Cancer Institute. Monographs.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

J. Crowley, G. Demetri, R. Maki, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, N. Girard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, N. Girard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2006, British journal of haematology.

High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants

J. Crowley, B. Barlogie, B. Cheson, 1994 .

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.

J. Crowley, B. Barlogie, T. Grogan, 2002, Blood.

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

J. Crowley, B. Barlogie, M. Dhodapkar, 2001, Blood.

Randomization and statistical power: paramount in trial reproducibility (even for rare cancers).

J. Crowley, R. Maki, L. Baker, 2012, The oncologist.

Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial.

J. Crowley, D. Moore, R. Livingston, 1999, The cancer journal from Scientific American.

The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer

Kari Chansky, J. Crowley, J. V. van Meerbeeck, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

J. Crowley, J. Jett, K. Kelly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Gemcitabine and Cisplatin in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group Study 9718

J. Crowley, K. Kelly, V. Israel, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group 9914

J. Crowley, K. Kelly, G. Weiss, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Confidence Interval for the Median Survival Time

Ron Brookmeyer, J. Crowley, R. Brookmeyer, 1982 .

Patient income level and cancer clinical trial participation.

J. Crowley, C. Moinpour, J. Unger, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.

J. Crowley, D. Gandara, P. Lara, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results

J. Crowley, B. Barlogie, D. Moore, 2008 .

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

Jack Cuzick, R. Collins, J. Crowley, 1988 .

Randomized Phase III Clinical Trial Designs for Targeted Agents

Antje Hoering, M. LeBlanc, J. Crowley, 2008, Clinical Cancer Research.

Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II Trial of the Southwest Oncology Group (S0027)

J. Crowley, J. Doroshow, C. Moinpour, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.

J. Crowley, K. Stelzer, V. Rusch, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.

J. Crowley, E. Perez, G. Weiss, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.

J. Crowley, M. Leblanc, R. Livingston, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2

J. Crowley, F. Hirsch, A. Wozniak, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A southwest oncology group study

J. Crowley, R. Livingston, J. W. Goodwin, 2007, Investigational New Drugs.

Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy.

J. Crowley, J. Villano, K. Chansky, 2020, Clinical lung cancer.

Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.

J. Crowley, C. Coltman, H. McLeod, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.

J. Crowley, M. Leblanc, R. Livingston, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

(Southwest Oncology Group S9003) Waldenström macroglobulinemia: results of United States intergroup trial Prognostic factors and response to fludarabine therapy in patients with

J. Crowley, B. Barlogie, M. Dhodapkar, 2013 .

Prognostic Groups by Tree-Based Partitioning and Data Refinement Methods

John Crowley, Michael LeBlanc, M. LeBlanc, 2012 .

Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).

J. Crowley, B. Barlogie, A. Jakubowiak, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Suppression of abnormal karyotype predicts superior survival in multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2008, Leukemia.

ORIGINAL ARTICLE Suppression of abnormal karyotype predicts superior survival in multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2008 .

Constructing Prognostic Groups by Tree-Based Partitioning and Peeling Methods

John Crowley, Michael LeBlanc, Erik Rasmussen, 2005 .

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.

J. Crowley, B. Barlogie, M. Dhodapkar, 2004, Blood.

Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials.

J. Crowley, B. Barlogie, J. Jacobson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience

J. Crowley, B. Barlogie, J. Jacobson, 2003, British journal of haematology.

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia : results of United States intergroup trial ( Southwest Oncology Group S 9003 )

J. Crowley, B. Barlogie, M. Dhodapkar, 2001 .

Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.

J. Crowley, J. Crowley, S. Balcerzak, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Some Exploratory Tools for Survival Analysis

John Crowley, Michael LeBlanc, Joth Jacobson, 1997 .

Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.

J. Crowley, K. Kelly, P. Bunn, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploratory methods in survival analysis

R. Gentleman, M. LeBlanc, J. Crowley, 1995 .

Neoadjuvant therapy: A novel and effective treatment for stage IIIb non-small cell lung cancer

J. Crowley, K. Stelzer, V. Rusch, 1994 .

A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study.

J. Crowley, J. Crowley, H. Eyre, 1993, Journal of neurosurgery.

A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study.

J. Crowley, C. Coltman, R. Livingston, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study.

J. Crowley, T. Miller, R. Livingston, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nonparametric Inference for a Class of Semi-Markov Processes with Censored Observations

Joseph G. Voelkel, J. Crowley, J. Voelkel, 1984 .

Some test statistics for use in multistate survival analysis

F. Y. Hsieh, J. Crowley, F. Hsieh, 1983 .

Estimation of the ratio of hazard functions

J. Crowley, J. Voelkel, P. Y. Liu, 1982 .

Asymptotic Normality of a New Nonparametric Statistic for Use in Organ Transplant Studies

John J. Crowley, J. Crowley, 1974 .

Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study

A. D. Van den Abbeele, J. Crowley, D. Flieder, 2019, Clinical Cancer Research.

Use of Covariates in Randomization and Analysis of Clinical Trials

Michael LeBlanc, M. LeBlanc, J. Crowley, 2012 .

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.

Mary W Redman, Karen Kelly, J. Crowley, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.

J. Crowley, P. Bunn, R. Livingston, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.

J. Crowley, D. Moore, D. Gandara, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.

J. Crowley, R. Livingston, S. Balcerzak, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.

J. Crowley, K. Kelly, P. Bunn, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of Multiple Models to Distinguish Closely Related Forms of Disease Using DNA Microarray Data: an Application to Multiple Myeloma

Johanna S. Hardin, C. D. Page, J. Hardin, 2004, Statistical applications in genetics and molecular biology.

Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer’s Disease by Vitamin E and Selenium Trial (PREADViSE)

J. Crowley, P. Goodman, F. Schmitt, 2017, JAMA neurology.

Phase II study of Fludarabine Phosphate in multiple myeloma

M. Grever, J. Crowley, E. Kraut, 1990, Investigational New Drugs.

Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.

J. Crowley, W. Chey, D. Morgan, 2013, JAMA.

The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the N and M Components for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors

J. Crowley, G. Giaccone, A. Nicholson, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033

J. Crowley, K. Owzar, J. Fletcher, 2017, JAMA oncology.

Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.

J. Crowley, G. Hortobagyi, S. Ramsey, 2013, Contemporary clinical trials.

A Diagnostic for Cox Regression and General Conditional Likelihoods

J. Crowley, B. Storer, John Crowley, 1985 .

Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial.

J. Crowley, R. Ginsberg, P. Bunn, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

Susan Groshen, Larry Rubinstein, Lesley Seymour, 2010, Clinical Cancer Research.

Multiple Histology Phase II Trials

John Crowley, Michael Leblanc, Cathryn Rankin, 2009, Clinical Cancer Research.

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)

J. Crowley, B. Barlogie, G. Morgan, 2016, Blood Cancer Journal.

Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents

Antje Hoering, M. LeBlanc, J. Crowley, 2010, Clinical Cancer Research.

Randomized Phase II Designs

Larry Rubinstein, John Crowley, Percy Ivy, 2009, Clinical Cancer Research.

Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer

J. Crowley, G. Weiss, R. Livingston, 1993, Investigational New Drugs.

Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors

J. Crowley, R. Korn, 2013, Clinical Cancer Research.

Age-Expanded Normative Data for the Ruff 2&7 Selective Attention Test: Evaluating Cognition in Older Males

J. Crowley, F. Schmitt, E. Abner, 2012, The Clinical neuropsychologist.

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

J. Crowley, B. Barlogie, E. Tian, 2016, Blood Cancer Journal.

VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2008, Leukemia.

International prognostic scoring system for Waldenström s Macroglobulinemia Short title: Prognostic index for Waldenström Macroglobulinemia

J. Crowley, B. Barlogie, M. Dimopoulos, 2017 .

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.

J. Crowley, B. Barlogie, P. Moreau, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical trial designs for multiple myeloma.

J. Crowley, A. Hoering, 2007, Clinical advances in hematology & oncology : H&O.

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)

J. Crowley, B. Barlogie, G. Morgan, 2015, Haematologica.

Statistics in Clinical Cancer Research CureModels asaUseful Statistical Tool forAnalyzingSurvival

M. LeBlanc, J. Crowley, B. Barlogie, 2012 .

Handbook of statistics in clinical oncology

Donna P. Ankerst, J. Crowley, D. Ankerst, 2012 .

Selection designs for pilot studies based on survival.

P Y Liu, S Dahlberg, J Crowley, 1993, Biometrics.

Vindesine. A phase II trial in advanced breast cancer patients.

J. Crowley, D. Tormey, G. Ramírez, 1981, Cancer clinical trials.

Making progress in treating multiple myeloma with total therapies: issue of complete remission and more

J. Crowley, B. Barlogie, J. Shaughnessy, 2008, Leukemia.

Making progress in treating multiple myeloma with total therapies: issue of complete remission and more

J. Crowley, B. Barlogie, J. Shaughnessy, 2008, Leukemia.

Reply to J. Mehta

J. Crowley, B. Barlogie, J. Shaughnessy, 2011 .

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2012, Leukemia.

Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): Update of Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials.

J. Crowley, B. Barlogie, J. Harousseau, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analyzing survival data from clinical trials and observational studies

J. Crowley, John Crowley, 1996 .

Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.

J. Crowley, B. Barlogie, J. Shaughnessy, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial

J. Crowley, P. Goodman, C. Tangen, 2016, Trials.

A randomized controlled Alzheimer’s disease prevention trial’s evolution into an exposure trial: The preadvise trial

J. Crowley, P. Goodman, F. Schmitt, 2012, The journal of nutrition, health & aging.

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)

J. Crowley, M. Hidalgo, N. Raghunand, 2014, Cancer Chemotherapy and Pharmacology.

396: Remarks on the Conservatism of Σ(0 - E) 2 /E in Survival Data

N. Breslow, J. Crowley, 1975 .

How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment.

David Veenstra, Scott D Ramsey, Louis Garrison, 2011, Health affairs.

A randomized controlled trial of vitamin E and selenium on rate of decline in lung function

J. Crowley, P. Goodman, C. Tangen, 2015, Respiratory Research.

Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.

J. Crowley, K. Kelly, C. Presant, 2002, Journal of the National Cancer Institute.

Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team.

J. Crowley, M. Kris, R. Ginsberg, 2000, The Journal of thoracic and cardiovascular surgery.

Survival Analysis with Gene Expression Arrays

Johanna Hardin, Michael LeBlanc, James R. Faulkner, 2003, Advances in Survival Analysis.

Clinical Trials in Oncology

Stephanie Green, Jacqueline Benedetti, J. Crowley, 1997 .

Chest irradiation (RT) vs. chest RT + chemotherapy ± prophylactic brain RT in localized non small cell lung cancer: A southwest oncology group randomized study

J. Crowley, T. Miller, J. Mira, 1990 .

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

J. Crowley, B. Barlogie, J. Epstein, 2013, Leukemia.

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6

J. Crowley, D. Gandara, K. Chansky, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Probability of Being in Response Function and Its Applications

J. Crowley, W. Tsai, Xiaodong Luo, 2017 .

Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung

J. Crowley, J. Doroshow, R. Livingston, 1992, Investigational New Drugs.

Semiparametric Regression Functionals

M. LeBlanc, J. Crowley, 1995 .

Interim futility analysis with intermediate endpoints

Michael LeBlanc, Bryan Goldman, M. LeBlanc, 2008, Clinical trials.

Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study.

J. Crowley, D. Reinke, R. Benjamin, 2010 .

Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.

Edward S. Kim, J. Crowley, R. Herbst, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker-based methods for determining noncompliance in a prevention trial.

J. Crowley, I. Thompson, D. Pauler, 2002, Controlled clinical trials.

The Evaluation of Gemcitabine in Resistant or Relapsing Multiple Myeloma, Phase II: a Southwest Oncology Group Study

J. Crowley, B. Barlogie, D. Moore, 2002, Investigational New Drugs.

A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas.

J. Crowley, D. Reinke, R. Maki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Clinical Trial Design for Noncytotoxic Anticancer Agents for which Time to Disease Progression is the Primary Endpoi t Running title : Phase II Trial Design for Time to Progression

R. Carroll, J. Crowley, R. Mick, 2000 .

Long-term survival with gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126

J. Crowley, F. Hirsch, D. Gandara, 2008 .

A note on nonparametric estimators of the bivariate survival function under univariate censoring

Wei-Yann Tsai, J. Crowley, W. Tsai, 1998 .

Small randomized trials.

Mary Redman, J. Crowley, John Crowley, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design

J. Crowley, S. Matsui, 2017, Clinical Cancer Research.

Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033.

J. Crowley, G. Demetri, C. Blanke, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial.

J. Crowley, P. Goodman, F. Schmitt, 2012, The journal of nutrition, health & aging.

A Reanalysis of the Stanford Heart Transplant Data: Comment

J. Crowley, B. Storer, John Crowley, 1983 .

Practice effects in a longitudinal, multi-center Alzheimer’s disease prevention clinical trial

J. Crowley, F. Schmitt, E. Abner, 2012, Trials.

Alternative measures predicting clinical benefit in advanced non-small cell lung cancer (NSCLC) from Southwest Oncology Group (SWOG) randomized trials: Implications for clinical trial design.

J. Crowley, K. Kelly, D. Gandara, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.

J. Crowley, R. Govindan, V. Bolejack, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study.

J. Crowley, C. Coltman, G. Weiss, 1986, Cancer treatment reports.

Commentary on PBT-1 study of high-dose consolidation versus standard therapy in metastatic breast cancer.

J. Crowley, R. Livingston, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A review of tree-based prognostic models.

M LeBlanc, J Crowley, M. LeBlanc, 1995, Cancer treatment and research.

Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents

Antje Hoering, Michael LeBlanc, Alan Mitchell, 2013, Clinical trials.

Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials.

J. Crowley, P. Catalano, M. Leblanc, 2014, Clinical cancer research : an official journal of the American Association for Cancer Research.

Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials.

J. Crowley, N. Saijo, Y. Nishiwaki, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819

J. Crowley, R. Herbst, F. Hirsch, 2012, Clinical Cancer Research.

DesignofaPhaseIIIClinicalTrialwithProspectiveBiomarker Validation: SWOG S0819

J. Crowley, R. Herbst, F. Hirsch, 2012 .

On robust estimation of location for arbitrarily right-censored data

Stephanie Green, J. Crowley, S. Green, 1986 .

The Automatic Clinical Trial: Leveraging the Electronic Medical Record in Multisite Cancer Clinical Trials

Judy Krueger, J. Crowley, John Crowley, 2012, Current Oncology Reports.

Freund's bivariate exponential distribution and censoring

Sue Leurgans, Wei-Yann Tsai, S. Leurgans, 1982 .

The IASLC Lung Cancer Staging Project: A Renewed Call to Participation.

J. Crowley, V. Rusch, R. Rami-Porta, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial

J. Crowley, W. Chey, D. Morgan, 2011, The Lancet.

Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy.

J. Crowley, R. Herbst, K. Kelly, 2005, Clinical lung cancer.

Nonparametric tests of the Markov model for survival data

J. Crowley, Michael P. Jones, John Crowley, 1992 .

The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho-Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer

J. Crowley, V. Rusch, R. Rami-Porta, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer

J. Crowley, P. Postmus, E. Brambilla, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy for Targeted Agents Seamless Phase I-II Trial Design for Assessing Toxicity and

M. LeBlanc, J. Crowley, A. Hoering, 2011 .

Second Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for testing population-related pharmacogenomics.

J. Crowley, D. Gandara, P. Mack, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estimation of Cumulative Incidence in the Presence of Competing Risks

J. Crowley, B. Storer, W. Leisenring, 2005 .

Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

J. Crowley, M. Spitz, J. Stanford, 2004, Cancer Causes and Control.

Nonparametric Estimation of a Bivariate Survival Function in the Presence of Censoring

Sue Leurgans, Wei-Yann Tsai, S. Leurgans, 1986 .

D. Berry, J. Crowley, S. Groshen, 2010, Clinical Cancer Research.

国际肺癌研究会分期项目——采用外科治疗的非小细胞肺癌的预后因素和病理TNM分期

J. Crowley, K. Chansky, P. Goldstraw, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

J. Crowley, D. Pauler, P. Goodman, 2004, The New England journal of medicine.

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, A. Nicholson, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer

J. Crowley, J. V. van Meerbeeck, K. Chansky, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents

M. LeBlanc, J. Crowley, A. Hoering, 2010, Clinical Cancer Research.

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

J. Crowley, B. Barlogie, M. Dhodapkar, 2001, Blood.

Randomized Phase III Clinical Trial Designs for Targeted Agents

M. LeBlanc, J. Crowley, A. Hoering, 2008, Clinical Cancer Research.

Teniposide (VM‐26) as a single drug treatment for patients with extensive small cell lung carcinoma

J. Crowley, G. Weiss, R. Livingston, 1997, Cancer.

Phase II with Multiple Subgroups: Designs Incorporating Disease Subtype or Genetic Heterogeneity

M. LeBlanc, J. Crowley, C. Rankin, 2012 .

Phase III Trials for Targeted Agents

M. LeBlanc, J. Crowley, A. Hoering, 2012 .

Randomized Phase II Designs

M. LeBlanc, J. Crowley, D. Sargent, 2009, Clinical Cancer Research.

Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341)

J. Crowley, A. Wozniak, D. Gandara, 2007 .

Statistical analysis of survival data.

N. Breslow, J. Crowley, 1984, Annual review of public health.